secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001178913-26-000067
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion CEO letter details 2025 progress; Phase 2/3 trial in LAPC set for H1 2026
--------------------------------------------------------------------------------

- SIL204 showed >90% inhibition in human cancer cell lines across 8 KRAS mutations and 5 tumor types.
- Positive regulatory feedback from Germany's BfArM on Phase 2/3 design; toxicology studies completed.
- Phase 2/3 LAPC trial initiation planned H1 2026; US IND expected H2 2026.
- Company raised over $18M in 2025 and regained Nasdaq compliance; addressable market >$30B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326000067/0001178913-26-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326000067/zk2634187.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer